Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 150 Colorectal Neoplasms 82 Stomach Neoplasms 77 Neoplasms 35 Neoplasm Metastasis 35 Pancreatic Neoplasms 25 Triple Negative Breast Neoplasms 22 Parkinson Disease 4, Autosomal Dominant Lewy Body 16 Adenocarcinoma 13 Esophageal Neoplasms 12 Carcinoma, Non-Small-Cell Lung 11 Colonic Neoplasms 10 Biliary Tract Neoplasms 10 Rectal Neoplasms 9 Carcinoma, Hepatocellular 9 Brain Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 7 Adenocarcinoma Of Esophagus 7 Solid Tumor 6 Ovarian Neoplasms 6 Cholangiocarcinoma 6 Nasopharyngeal Carcinoma 5 Gastrointestinal Neoplasms 5 Esophageal Squamous Cell Carcinoma 5 Recurrence 4 Nasopharyngeal Neoplasms 4 Advanced Solid Tumors 4 Sarcoma 3 Melanoma 3 Head and Neck Neoplasms 3

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Pan-tumor × Capecitabine × Clear all

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co., Ltd.

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡